Geftiget Tablets 250mg

Product Description

Geftiget Tablets 250mg are a targeted anticancer treatment used for managing advanced or metastatic non-small cell lung cancer (NSCLC), particularly in patients whose tumors carry specific EGFR mutations. By blocking cancer cell growth signals, the medication helps slow disease progression and improve respiratory symptoms.

Product Overview

Product Name: Geftiget Tablets 250mg
Product Form: Tablets
Pack Size: 10's
Manufactured By: GLS Pharma
Used For: Treatment of EGFR-mutated non-small cell lung cancer
Prescription Required: Yes

How It Works

Geftiget contains a targeted therapy that inhibits the epidermal growth factor receptor (EGFR), a protein that drives cancer cell growth and division. In patients with EGFR-mutated NSCLC, the receptor is overactive, leading to uncontrolled tumor development. By blocking EGFR signaling pathways, the medication helps stop cancer cells from multiplying and assists in shrinking or slowing the progression of tumors.

Key Benefits

Effective treatment for EGFR-mutated non-small cell lung cancer.
Often used as first-line therapy for advanced or metastatic NSCLC.
Helps slow tumor progression and reduce cancer-related symptoms.
Supports improved breathing and overall quality of life.

How to Use

Take Geftiget Tablets exactly as prescribed by your oncologist.
Typically taken once daily with or without food.
Swallow the tablet whole without crushing or breaking it.

Side Effects and Precautions

Common Side Effects

Skin rash or acne-like eruptions
Diarrhea
Nausea or vomiting
Fatigue or weakness
Dry skin or itching

Serious Side Effects

Interstitial lung disease (ILD), causing cough, fever, or breathing difficulty
Liver toxicity with elevated liver enzymes
Severe diarrhea leading to dehydration
Gastrointestinal perforation (rare)

Precautions

Genetic testing for EGFR mutations is required before starting therapy.
Regular monitoring of liver and lung function is essential.
Watch for signs of dehydration, especially if experiencing diarrhea.
Avoid strong CYP3A4 enzyme inducers such as phenytoin or rifampin.
Antacids or proton pump inhibitors may affect absorption; consult your doctor for proper timing.
Avoid during pregnancy and use effective contraception during treatment and afterward.
Not recommended during breastfeeding.
Maintain adequate hydration throughout treatment.

Who Should Use

Patients diagnosed with EGFR-positive non-small cell lung cancer and prescribed this medication by an oncology specialist.

Storage Instructions

Store in a cool, dry place away from direct sunlight.
Keep out of reach of children and ensure the medication is used before expiry.

Disclaimer

This medication must be used under medical supervision. The information provided does not replace professional medical advice. Always consult your doctor for diagnosis, treatment planning, and correct dosing instructions.